JP5955236B2 - Blood cresol lowering agent - Google Patents
Blood cresol lowering agent Download PDFInfo
- Publication number
- JP5955236B2 JP5955236B2 JP2013016429A JP2013016429A JP5955236B2 JP 5955236 B2 JP5955236 B2 JP 5955236B2 JP 2013016429 A JP2013016429 A JP 2013016429A JP 2013016429 A JP2013016429 A JP 2013016429A JP 5955236 B2 JP5955236 B2 JP 5955236B2
- Authority
- JP
- Japan
- Prior art keywords
- cresol
- blood
- renal failure
- patients
- indigestible dextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008280 blood Substances 0.000 title claims description 63
- 210000004369 blood Anatomy 0.000 title claims description 63
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 title claims description 49
- 229930003836 cresol Natural products 0.000 title claims description 49
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 48
- 201000006370 kidney failure Diseases 0.000 claims description 48
- 229920001353 Dextrin Polymers 0.000 claims description 30
- 239000004375 Dextrin Substances 0.000 claims description 30
- 235000019425 dextrin Nutrition 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 235000016709 nutrition Nutrition 0.000 claims description 17
- 239000003638 chemical reducing agent Substances 0.000 claims description 14
- 238000000502 dialysis Methods 0.000 claims description 13
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 8
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 8
- 208000019553 vascular disease Diseases 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 3
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 26
- 241000700159 Rattus Species 0.000 description 9
- 208000017169 kidney disease Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 7
- 235000020805 dietary restrictions Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- YQUQWHNMBPIWGK-UHFFFAOYSA-N 4-isopropylphenol Chemical compound CC(C)C1=CC=C(O)C=C1 YQUQWHNMBPIWGK-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000013059 nephrectomy Methods 0.000 description 2
- WGNAKZGUSRVWRH-UHFFFAOYSA-N p-cresol sulfate Chemical compound CC1=CC=C(OS(O)(=O)=O)C=C1 WGNAKZGUSRVWRH-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000008373 coffee flavor Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、腎不全患者におけるクレゾールの血中濃度を低下するための血中クレゾール低下剤に関する。
また、本発明は、腎不全患者における食事制限のもとで、クオリティー・オブ・ライフ（ＱＯＬ）改善に繋がる栄養組成物形態の血中クレゾール低下剤に関する。
The present invention relates to a blood cresol reducing agent for reducing the blood concentration of cresol in patients with renal failure.
The present invention also relates to a blood cresol-lowering agent in the form of a nutritional composition that leads to quality of life (QOL) improvement under dietary restrictions in patients with renal failure.
ｐ−クレゾール（以下、単に「クレゾール」ともいう。）は、腸内細菌によって蛋白質由来のチロシン及びフェニルアラニンから産生される物質であり、腸内腐敗産物として知られている。クレゾールは、尿毒症物質の一つとされ、血中におけるクレゾール濃度の増加は、人体に対して悪影響を及ぼすとされている。
血液中のクレゾールは、主に硫酸抱合体（ｐ−クレシル硫酸）で存在し、アルブミンと結合した状態で循環していると考えられている。
正常な腎機能のもとでは、血中のクレゾールは尿により排泄され、その血中濃度は低く保たれている。しかしながら、腎機能が低下した腎不全患者（透析患者含む）では、血中のクレゾールの尿による排泄が正常に行われず、その血中濃度が高くなっている。
p-cresol (hereinafter, also simply referred to as “cresol”) is a substance produced from protein-derived tyrosine and phenylalanine by intestinal bacteria, and is known as an intestinal spoilage product. Cresol is considered as one of uremic substances, and an increase in the concentration of cresol in the blood is considered to have an adverse effect on the human body.
Cresol in blood exists mainly as a sulfate conjugate (p-cresyl sulfate), and is thought to circulate in a state of being bound to albumin.
Under normal renal function, cresol in the blood is excreted by urine, and its blood concentration is kept low. However, in renal failure patients (including dialysis patients) whose renal function has been reduced, urinary excretion of cresol in the blood is not performed normally, and the blood concentration is high.
近年、腎不全患者の血中のクレゾールが、生命予後、及び血管障害、免疫低下などの様々な病態、症状と関連していることが指摘されている（非特許文献１〜１５など）。 In recent years, it has been pointed out that cresol in the blood of patients with renal failure is associated with various prognosis and various pathologies and symptoms such as vascular disorders and immune decline (Non-Patent Documents 1 to 15, etc.).
上述した通り、クレゾールの産生には腸内細菌叢が関与していることから、生体におけるクレゾールの存在については、従来、他の腸内腐敗産物（アンモニア、フェノール、インドールなど）とともに、プレバイオティクス、プロバイオティクスの研究で取り上げられることが多い（特許文献１）。特許文献１には、乳酸菌製剤を有効成分とする慢性腎不全改善剤および透析患者のクオリティー・オブ・ライフ改善剤が記載されている。 As mentioned above, since the intestinal microflora is involved in the production of cresol, the presence of cresol in the living body has been conventionally prebiotic together with other intestinal spoilage products (ammonia, phenol, indole, etc.). It is often taken up in research on probiotics (Patent Document 1). Patent Document 1 describes a chronic renal failure ameliorating agent and a dialysis patient quality of life improving agent containing a lactic acid bacteria preparation as an active ingredient.
上述したように、腎不全患者においては、クレゾールの血中濃度を低下させることが要求される。
しかしながら、クレゾールは透析によって除去しにくいという問題がある（特許文献１参照）。
特許文献１には、乳酸菌製剤の投与により、糞便中のｐ−クレゾール濃度が低下したことについて記載されているが、血漿中のｐ−クレゾール濃度については、有意差が認められなかったことが記載されている。
そこで、本発明は、腎不全患者において、クレゾールの血中濃度を低下させる手段を提供することを課題とする。
また、腎不全患者においては、水分、電解質、栄養素等の摂取量などの許容範囲が狭く、厳密な食事制限が必要とされている。そのため、腎不全患者においては、その熱量や成分をコントロールした栄養組成物の摂取が必須である場合が多い。
そこで、本発明は、腎不全患者における栄養補給に用いられる組成物、すなわち栄養組成物であって、クレゾールの血中濃度を低下させるための栄養組成物を提供することを課題とする。
As described above, in patients with renal failure, it is required to reduce the blood concentration of cresol.
However, there is a problem that cresol is difficult to remove by dialysis (see Patent Document 1).
Patent Document 1 describes that p-cresol concentration in feces was reduced by administration of a lactic acid bacteria preparation, but no significant difference was found in p-cresol concentration in plasma. Has been.
Then, this invention makes it a subject to provide the means to reduce the blood concentration of cresol in a renal failure patient.
In patients with renal failure, the allowable range of intake of water, electrolytes, nutrients and the like is narrow, and strict dietary restrictions are required. Therefore, in patients with renal insufficiency, it is often essential to take a nutritional composition that controls the amount of heat and ingredients.
Therefore, an object of the present invention is to provide a composition used for nutritional supplementation in patients with renal failure, that is, a nutritional composition, for reducing the blood concentration of cresol.
前記課題を解決する本発明は、難消化性デキストリンを有効成分とする、腎不全（但し、糖尿病性腎症から生じる腎不全を除く）の透析患者用の血管障害治療のための血中クレゾール低下剤である。
本発明の血中クレゾール低下剤は、腎不全（但し、糖尿病性腎症から生じる腎不全を除く）の透析患者におけるクレゾールの血中濃度を有意に低下させるものである。また、本発明の血中クレゾール低下剤の有効成分である難消化性デキストリンは、食品原料としても知られるものであり、安全性が高い。
The present invention that solves the above-mentioned problems is a reduction in blood cresol for the treatment of vascular disorders for dialysis patients with renal failure (excluding renal failure resulting from diabetic nephropathy), comprising indigestible dextrin as an active ingredient. It is an agent.
The blood cresol reducing agent of the present invention significantly reduces the blood concentration of cresol in dialysis patients with renal failure (excluding renal failure resulting from diabetic nephropathy) . Indigestible dextrin, which is an active ingredient of the blood cresol reducing agent of the present invention, is also known as a food material and has high safety.
本発明にいう「治療」は、症状を改善させること、症状の悪化を防ぐことを含む。 “Treatment” as used in the present invention includes improving symptoms and preventing worsening of symptoms.
本発明の好ましい形態では、前記血中クレゾール低下剤は、難消化性デキストリンを、１日あたり３ｇ以上投与して用いるためのものである。
すなわち、腎不全（但し、糖尿病性腎症から生じる腎不全を除く）の透析患者において、難消化性デキストリンを投与する場合において、１日あたりの難消化性デキストリンの投与量を所定量以上とすることにより、クレゾールの血中濃度を低下させることが可能となる。
In a preferred form of the present invention, the blood cresol-lowering agent is used for administration of 3 g or more of indigestible dextrin per day.
That is, when administering indigestible dextrin in dialysis patients with renal failure (excluding renal failure resulting from diabetic nephropathy), the dose of indigestible dextrin per day is set to a predetermined amount or more. As a result, the blood concentration of cresol can be lowered.
本発明の好ましい形態では、前記血中クレゾール低下剤は、難消化デキストリンが、１日あたりの有効量として３ｇ以上、好ましくは３〜８ｇ、特に好ましくは６〜８ｇとなるように経口栄養組成物に含有されて提供されることがよい。
このような形態の血中クレゾール低下剤は、腎不全（但し、糖尿病性腎症から生じる腎不全を除く）の透析患者において必要となる食事制限の下でも、必要なエネルギーを摂取しながら、しかもクレゾールの血中濃度を低下させることを可能とするものである。
このような形態の血中クレゾール低下剤は、クレゾールの血中濃度を低下させることを実現しながら、効率よいエネルギー補給を可能とするものであり、腎不全（但し、糖尿病性腎症から生じる腎不全を除く）の透析患者のクオリティー・オブ・ライフ（ＱＯＬ）の向上に有用である。
In a preferred form of the present invention, the blood cresol reducing agent is an oral nutritional composition so that the amount of indigestible dextrin is 3 g or more, preferably 3 to 8 g, particularly preferably 6 to 8 g per day. It is good to be provided and contained.
Such a form of blood cresol lowering agent can be used while taking the necessary energy even under dietary restrictions required in dialysis patients with renal failure (excluding renal failure resulting from diabetic nephropathy). It is possible to reduce the blood concentration of cresol.
Such a form of blood cresol lowering agent enables efficient energy supply while realizing a reduction in blood concentration of cresol, and renal failure (however, kidneys resulting from diabetic nephropathy) It is useful for improving the quality of life (QOL) of dialysis patients ( excluding failure) .
本発明の好ましい形態では、前記血中クレゾール低下剤は、液状又はゲル状の栄養組成物の形態で用いられるものである。 In a preferred embodiment of the present invention, the blood cresol reducing agent is used in the form of a liquid or gel nutritional composition.
本発明によれば、腎不全患者におけるクレゾールの血中濃度を低下させることができる。これにより、血中クレゾール濃度の増加により引き起こされる様々な病態、疾患、症状の発生、悪化のリスクを低減させることが可能となる。その結果として、腎不全患者の死亡リスクを低減させることが可能となる。
また、本発明の血中クレゾール低下剤は、有効成分として、従来、食品原料などに用いられている難消化性デキストリンを含有させることができるため、安全性に優れるものである。
特に、本発明の栄養組成物の形態の血中クレゾール低下剤は、腎不全患者における食事制限のもとで、血中クレゾール濃度の増加により引き起こされる様々な病態、疾患、症状の発生、悪化のリスクを低減させることを可能とするものであり、腎不全患者のクオリティー・オブ・ライフ（ＱＯＬ）改善に大きく寄与するものである。
According to the present invention, the blood concentration of cresol in patients with renal failure can be reduced. Thereby, it becomes possible to reduce the risk of occurrence of various pathologies, diseases, and symptoms caused by an increase in blood cresol concentration. As a result, it becomes possible to reduce the risk of death of patients with renal failure.
Moreover, since the blood cresol reducing agent of this invention can contain the indigestible dextrin conventionally used for the food raw material etc. as an active ingredient, it is excellent in safety | security.
In particular, the blood cresol-lowering agent in the form of the nutritional composition of the present invention is effective in the development and deterioration of various pathologies, diseases, and symptoms caused by an increase in blood cresol concentration under dietary restrictions in patients with renal failure. It makes it possible to reduce the risk and greatly contributes to the improvement of quality of life (QOL) of patients with renal failure.
以下、本発明を実施するための形態について説明する。
本発明の血中クレゾール低下剤は、腎不全患者において、血中のクレゾール濃度を低下させるためのものである。すなわち、腎機能の不全により血液中のクレゾール濃度が増加している状態に対して、そのクレゾール濃度を低下させるためのもの、又は腎機能の不全により血液中のクレゾール濃度が増加し得る状態において、血中のクレゾール濃度を増加させないためのものである。
Hereinafter, modes for carrying out the present invention will be described.
The blood cresol reducing agent of the present invention is for lowering blood cresol concentration in patients with renal failure. That is, for a state where the cresol concentration in the blood is increased due to renal function failure, in order to reduce the cresol concentration, or in a state where the cresol concentration in the blood can be increased due to renal function failure, This is to prevent blood cresol concentration from increasing.
腎不全患者としては、例えば、慢性糸球体腎炎、糖尿病性腎症、腎硬化症、多発性嚢胞腎等の慢性腎臓病（ＣＫＤ）、急性腎臓病、ネフローゼ症候群等の患者が挙げられる。
また、上記腎疾患の病期（ステージ）も特に制限されない。ステージ１〜５、透析患者（ステージ５Ｄ）の何れの患者にも使用することが可能である。また、本発明の血中クレゾール低下剤は、透析患者にも好適に用いることができる。これは、クレゾールは、透析によって除去しにくい物質であるためである（特許文献１参照）。
Examples of renal failure patients include patients with chronic glomerulonephritis, diabetic nephropathy, nephrosclerosis, chronic kidney disease such as polycystic kidney disease (CKD), acute kidney disease, nephrotic syndrome, and the like.
Moreover, the stage (stage) of the kidney disease is not particularly limited. It can be used for any of stage 1-5 patients and dialysis patients (stage 5D). Moreover, the blood cresol reducing agent of this invention can be used suitably also for a dialysis patient. This is because cresol is a substance that is difficult to remove by dialysis (see Patent Document 1).
本発明の血中クレゾール低下剤の有効成分である難消化性デキストリンは、特に限定されないが商品名「パインファイバー」、「ファイバーソル２」（松谷化学工業（株）製）、「オクノス食物繊維」（ホリカフーズ（株）製）、「ニュートリオース ＦＢ０６」（ロケットジャパン（株）製）などの、澱粉及び小麦粉を加熱、酵素処理して得られる難消化性の食物繊維を用いることができる。
具体的には例えば、澱粉を酸性下で加熱処理して得られる焙焼デキストリンを、α−アミラーゼで加水分解処理し、さらに必要に応じて、グルコアミラーゼ処理、イオン交換樹脂クロマトグラフィー処理などの精製処理などを施して得ることができる。その分子量は、特に限定されないが、好ましくは５００〜１０，０００の範囲のものを用いることができる。分子量が５００未満のものは呈味性の面で、また分子量１０，０００以上のものは呈味性、食感の面で劣るものもあるので、本発明においては、分子量は５００〜１０，０００であることが良い。
The indigestible dextrin which is an active ingredient of the blood cresol reducing agent of the present invention is not particularly limited, but trade names “Pine Fiber”, “Fiber Sol 2” (manufactured by Matsutani Chemical Industry Co., Ltd.), “Okunos Dietary Fiber” Indigestible dietary fiber obtained by heating and enzymatic treatment of starch and wheat flour (Horica Foods Co., Ltd.), "Nutriose FB06" (Rocket Japan Co., Ltd.) and the like can be used.
Specifically, for example, roasted dextrin obtained by heat-treating starch under acidic conditions is hydrolyzed with α-amylase and, if necessary, purified such as glucoamylase treatment or ion exchange resin chromatography treatment. It can be obtained by processing. The molecular weight is not particularly limited, but preferably a molecular weight in the range of 500 to 10,000 can be used. Those having a molecular weight of less than 500 are in terms of taste, and those having a molecular weight of 10,000 or more are inferior in taste and texture. Therefore, in the present invention, the molecular weight is 500 to 10,000. It is good to be.
本発明の血中クレゾール低下剤は、医薬の形態とすることが可能である。また、食品の形態として腎不全患者用の栄養組成物とすることも可能であり、経口、経管等のあらゆる摂取形態に可能な組成物とすることができる。
本発明の血中クレゾール低下剤の剤形は特に制限されない。たとえば、顆粒、粉末、カプセル、ペースト、ゲル剤、液剤などが好ましく挙げられる。製剤化においては、通常の賦形剤を用いることができ、乳糖等が好ましく用いられる。本発明の血中クレゾール低下剤は、上述した難消化性デキストリンを、必要に応じて賦形剤などを用い、常法により製剤化することで製造することができる。
The blood cresol reducing agent of the present invention can be in the form of a medicine. Moreover, it can also be set as the nutritional composition for renal failure patients as a form of a foodstuff, and it can be set as the composition which can be used in all intake forms, such as oral and a tube.
The dosage form of the blood cresol lowering agent of the present invention is not particularly limited. For example, granules, powders, capsules, pastes, gels, liquids and the like are preferable. In the formulation, ordinary excipients can be used, and lactose and the like are preferably used. The blood cresol reducing agent of the present invention can be produced by formulating the above-mentioned indigestible dextrin by a conventional method using an excipient or the like as necessary.
上述した形態において、本発明の血中クレゾール低下剤における難消化性デキストリンの含有量は、たとえば、２０〜１００質量％、好ましくは４０〜１００質量％、さらに好ましくは６０〜１００質量％とすることが可能である。すなわち、剤形が維持できる範囲であれば賦形剤は少ない方が好ましいので、有効量は１００％であっても良い。 In the above-described form, the content of indigestible dextrin in the blood cresol reducing agent of the present invention is, for example, 20 to 100% by mass, preferably 40 to 100% by mass, and more preferably 60 to 100% by mass. Is possible. That is, as long as the dosage form can be maintained, fewer excipients are preferable, so the effective amount may be 100%.
また、本発明の血中クレゾール低下剤は、腎不全患者用の栄養組成物の形態で提供することが特に好ましい。すなわち、腎不全患者は、厳格な食事制限を必要とするため、その摂取成分をコントロールした栄養組成物を用いて、必要なエネルギーを摂取することが重要とされている。
栄養組成物の形態で提供される血中クレゾール低下剤は、水分摂取量を抑える観点から、エネルギー換算で、例えば、１．０〜２．０ｋｃａｌ／ｍｌの高カロリーであることが好ましく、さらに摂取のしやすさの観点から、特に１．１〜１．３ｋｃａｌ／ｍｌとなるように調製することが好ましい。
また、腎不全患者用という観点から、１日投与単位の総熱量は、経口投与の場合で１５０〜３００ｋｃａｌ、経管投与の場合で９００〜１２００ｋｃａｌとすることが、通常好ましい。
経口投与の場合、難消化性デキストリンの含有量は、例えば、エネルギー１００ｋｃａｌあたり、好ましくは１ｇ以上、さらに好ましくは１〜５．４ｇ、より好ましくは２〜２．７ｇとすることができる。
また、このような栄養組成物の形態は、投与、摂取のしやすさから、液状、ゲル状のものなどが好ましい。
このような形態の血中クレゾール低下剤は、上記難消化性デキストリンの他、炭水化物、蛋白質、脂質、ミネラル、ビタミン等を食事摂取基準における必要量、推奨量等に基づいて、適宜含有するものである。
The blood cresol-lowering agent of the present invention is particularly preferably provided in the form of a nutritional composition for patients with renal failure. That is, since renal failure patients require strict dietary restrictions, it is important to take in the necessary energy using a nutritional composition in which the intake components are controlled.
The blood cresol-lowering agent provided in the form of a nutritional composition is preferably high-calorie, for example, 1.0 to 2.0 kcal / ml in terms of energy from the viewpoint of suppressing water intake. From the viewpoint of ease of treatment, it is particularly preferable to prepare it at 1.1 to 1.3 kcal / ml.
Further, from the viewpoint of use for patients with renal failure, it is usually preferable that the total calorie of the daily dosage unit is 150 to 300 kcal for oral administration and 900 to 1200 kcal for tube administration.
In the case of oral administration, the content of indigestible dextrin is, for example, preferably 1 g or more, more preferably 1 to 5.4 g, more preferably 2 to 2.7 g per 100 kcal of energy.
In addition, the form of such a nutritional composition is preferably liquid or gel-like from the viewpoint of ease of administration and ingestion.
Such a form of blood cresol-lowering agent suitably contains carbohydrates, proteins, lipids, minerals, vitamins, etc., in addition to the above-mentioned indigestible dextrin, based on the required and recommended amounts in the dietary intake standard. is there.
本発明の血中クレゾール低下剤の腎不全患者への投与量は、難消化性デキストリンの投与量として、３ｇ／日以上であり、好ましくは３〜８ｇ／日、特に好ましくは６〜８ｇ／日である。 The dose of the blood cresol-lowering agent of the present invention to a renal failure patient is 3 g / day or more, preferably 3 to 8 g / day, particularly preferably 6 to 8 g / day, as the dose of indigestible dextrin. It is.
本発明の血中クレゾール低下剤は、腎機能の不全が原因で引き起こされる血中クレゾール増加に伴う疾患、症状の治療剤とすることができる。
このような疾患、症状として、血管障害が挙げられる。血管障害としては、血管石灰化、血管内皮細胞の増殖低下、血管内皮細胞の透過性の上昇、血管内皮細胞の応答性の減弱、血小板凝集機能の低下、動脈硬化が挙げられる。また、上記疾患、症状として、免疫力の低下、心疾患、老化等が挙げられる。また、血中クレゾール濃度の増加は、さらなる腎機能の不全を引き起こすことも知られている。従って、本発明の血中クレゾール低下剤は、腎疾患の進行の予防のためにも用いることができる。
本発明の血中クレゾール低下剤は、腎不全患者における血管障害治療剤として用いることが好ましい。
The blood cresol-lowering agent of the present invention can be used as a therapeutic agent for diseases and symptoms associated with an increase in blood cresol caused by impaired renal function.
Examples of such diseases and symptoms include vascular disorders. Examples of the vascular disorder include vascular calcification, decreased proliferation of vascular endothelial cells, increased permeability of vascular endothelial cells, decreased responsiveness of vascular endothelial cells, decreased platelet aggregation function, and arteriosclerosis. Examples of the diseases and symptoms include decreased immunity, heart disease, and aging. It is also known that an increase in blood cresol concentration causes further renal failure. Therefore, the blood cresol-lowering agent of the present invention can also be used for preventing the progression of renal diseases.
The blood cresol-lowering agent of the present invention is preferably used as a vascular disorder therapeutic agent in patients with renal failure.
＜血中ｐ−クレゾールの測定試験＞
腎不全モデルラットである５／６腎臓摘出ラットを用いて、難消化性デキストリンによる血清ｐ−クレゾールの低下作用を検討した。
<Measurement test of blood p-cresol>
Using 5/6 nephrectomized rats, which are renal failure model rats, the effect of indigestible dextrin to lower serum p-cresol was examined.
具体的な方法は以下のとおりである。
試験には、腎不全群として、５／６腎臓摘出を実施したＳＤラット（８週齢，Crl:CD）１２匹を用いた。これらのラットを２週間馴化した後、表１に示すように６匹ずつをコントロール群と難消化性デキストリン投与群の２群に分け、それぞれの群に、表１に示す配合を有する難消化性デキストリンを含む飼料と難消化性デキストリンを含まない飼料を１週間自由摂取させた。また、非腎不全群として、腎臓摘出を実施しないＳＤラット（８週齢，Crl:CD）６匹に対し、難消化性デキストリンを含まない飼料を同様に自由摂取させた。
１週間の自由摂取後、各ラットを解剖して採血し、血清ｐ−クレゾール濃度を測定した。
ｐ−クレゾール濃度の測定方法は以下のとおりである。
β−グルクロニダーゼ及び酸性加熱処理により、抱合体及びアルブミン結合を除去後、塩化ナトリウムを添加し、酢酸エチルで抽出し、HPLC測定した。内部標準には、ｐ−イソプロピルフェノールを使用した。
なお、以下の表１において、％（パーセント）は、質量による記載である。
The specific method is as follows.
In the test, 12 SD rats (8-week-old, Crl: CD) subjected to 5/6 nephrectomy were used as the renal failure group. After acclimatizing these rats for 2 weeks, 6 rats were divided into 2 groups, a control group and an indigestible dextrin administration group, as shown in Table 1, and each group has indigestibility having the formulation shown in Table 1. A feed containing dextrin and a feed not containing indigestible dextrin were freely ingested for 1 week. In addition, as a non-renal failure group, 6 SD rats (8-week-old, Crl: CD) that were not subjected to nephrectomy were similarly given free intake of a diet that did not contain indigestible dextrin.
After one week of free intake, each rat was dissected and blood collected, and the serum p-cresol concentration was measured.
The measuring method of p-cresol concentration is as follows.
After removing the conjugate and albumin bond by β-glucuronidase and acidic heat treatment, sodium chloride was added, and the mixture was extracted with ethyl acetate and subjected to HPLC measurement. P-Isopropylphenol was used as an internal standard.
In Table 1 below,% (percent) is a description by mass.
結果を図１及び表２に示す。表２には、各群のラットの平均値と標準偏差を示した。 The results are shown in FIG. Table 2 shows the mean and standard deviation of each group of rats.
図１及び表２からわかるように、腎臓を摘出した腎不全群において、難消化性デキストリンを含まない飼料を与えたコントロール群では、血液中のｐ−クレゾール濃度は高値を示したが、難消化性デキストリンを含む飼料を与えた難消化性デキストリン投与群では、血液中のｐ−クレゾール濃度は低値を示した。その値は、非腎不全群における値と同等にまで低いものであった。
これより、難消化性デキストリンを腎不全のラットに投与することにより、血液中のｐ−クレゾール濃度を有意に低下させることができることが分かった。
As can be seen from FIG. 1 and Table 2, in the renal failure group in which the kidney was removed, in the control group to which the feed not containing indigestible dextrin was given, the p-cresol concentration in the blood showed a high value. In the indigestible dextrin administration group fed with a feed containing sex dextrin, the p-cresol concentration in blood showed a low value. The value was as low as that in the non-renal failure group.
From this, it was found that the p-cresol concentration in blood can be significantly reduced by administering indigestible dextrin to rats with renal failure.
次に実施例を示して本発明を詳記するが、本発明は以下の実施例に限定されるものではない。
＜実施例１＞
内容量が１２５ｍｌの腎疾患患者用経口栄養組成物（腎不全患者向けエネルギー補充用流動食：コーヒー風味）を、表３に記載される組成、成分量（エネルギー１００ｋｃａｌあたりの配合量）に基づいて常法により製造した。
EXAMPLES Next, although an Example is shown and this invention is explained in full detail, this invention is not limited to a following example.
<Example 1>
An oral nutritional composition for renal disease patients with an internal volume of 125 ml (liquid diet for energy supplementation for renal failure patients: coffee flavor) based on the composition and amount of ingredients (mixed amount per 100 kcal of energy) shown in Table 3 Manufactured in a conventional manner.
このような腎疾患患者用経口栄養組成物は、１００ｋｃａｌあたり、２．５ｇの難消化性デキストリンを含むものであり、これを一日あたり１５０〜３００ｋｃａｌ相当摂取することで、ｐ−クレゾールの血中濃度を低下させるのに効果的な難消化性デキストリンを摂取できるものである。すなわち、この腎疾患患者用経口栄養組成物は、血中ｐ−クレゾール低下剤として有用である。 Such an oral nutritional composition for patients with renal diseases contains 2.5 g of indigestible dextrin per 100 kcal, and by ingesting this equivalent to 150 to 300 kcal per day, Indigestible dextrin that is effective in reducing the concentration can be ingested. That is, this oral nutritional composition for patients with renal diseases is useful as a blood p-cresol reducing agent.
本発明の血中クレゾール低下剤は、腎不全患者の血管障害の治療に有用である。また、腎不全患者の生命予後に関与するといわれる血中ｐ−クレゾールを低下するために有用であり、及び食事療法に用いる栄養組成物として、極めて有用である。 The blood cresol-lowering agent of the present invention is useful for the treatment of vascular disorders in patients with renal failure. Moreover, it is useful for lowering blood p-cresol, which is said to be involved in the prognosis of patients with renal failure, and is extremely useful as a nutritional composition used in diet therapy.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013016429A JP5955236B2 (en) | 2013-01-31 | 2013-01-31 | Blood cresol lowering agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013016429A JP5955236B2 (en) | 2013-01-31 | 2013-01-31 | Blood cresol lowering agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014148467A JP2014148467A (en) | 2014-08-21 |
| JP5955236B2 true JP5955236B2 (en) | 2016-07-20 |
Family
ID=51571774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013016429A Active JP5955236B2 (en) | 2013-01-31 | 2013-01-31 | Blood cresol lowering agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5955236B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6801894B2 (en) * | 2016-10-31 | 2020-12-16 | 国立大学法人東北大学 | Agent for reducing blood uremic substances |
| JP6815632B2 (en) * | 2016-12-27 | 2021-01-20 | 国立大学法人東北大学 | Anti-sulfate phenyl derivative antibody |
| JP7141387B2 (en) * | 2017-04-21 | 2022-09-22 | 株式会社林原 | In vivo phenol compound reducing agent |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006082643A1 (en) * | 2005-02-03 | 2006-08-10 | Taiyo Kagaku Co., Ltd. | Preventive, relieving or therapeutic composition for diabetes mellitus and/or diabetic nephropathy |
-
2013
- 2013-01-31 JP JP2013016429A patent/JP5955236B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014148467A (en) | 2014-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11529364B2 (en) | Synthetic composition for treating metabolic disorders | |
| EP3349763B1 (en) | Composition for use in microbiota modulation | |
| Krebs | Update on zinc deficiency and excess in clinical pediatric practice | |
| Dutta et al. | Impact of zinc supplementation in malnourished children with acute watery diarrhoea | |
| WO2013174306A1 (en) | Infant formula milk powder and preparation method thereof | |
| EP2039365B1 (en) | Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level | |
| Sozo et al. | Effects of prenatal ethanol exposure on the lungs of postnatal lambs | |
| Kooshki et al. | A synbiotic supplement for inflammation and oxidative stress and lipid abnormalities in hemodialysis patients | |
| ES2856053T3 (en) | Synthetic composition and procedure to promote mucosal healing | |
| JP5955236B2 (en) | Blood cresol lowering agent | |
| Khosroshahi et al. | Lactulose for reduction of nitrogen products in patients with chronic kidney disease | |
| Wędrychowicz et al. | Total parenteral nutrition in children and adolescents treated with high-dose chemotherapy followed by autologous haematopoietic transplants | |
| US10835544B2 (en) | Synthetic composition for regulating satiety | |
| JP2012167069A (en) | Lipid metabolism-improving agent, functional food, food additive, antioxidant, pharmaceutical, arteriosclerosis prevention/improvement agent, cosmetic, and method of manufacturing lipid metabolism-improving agent | |
| JP2010111646A (en) | Treating agent for ulcerative colitis | |
| JP6088071B2 (en) | Serum uric acid lowering agent containing rice protein as active ingredient | |
| JP2007320900A (en) | Agent for inhibiting visceral fat accumulation and agent for promoting increase in and/or inhibiting decrease in blood adiponectin concentration | |
| Mali et al. | Review of risk factors of malnutrition in maintenance hemodialysis patients | |
| JP2013166741A (en) | Enteric hormone secretion control agent | |
| JP6749097B2 (en) | Agents for reducing or catabolizing protein catabolism | |
| Aparicio | Protein intake and chronic kidney disease: literature review, 2003 to 2008 | |
| EP2585103A1 (en) | Method of treatment | |
| JP2010150241A (en) | Agent for reducing acetaldehyde and ethanol | |
| TWI691334B (en) | Internally taken compositions, preparations, and uses | |
| Akram et al. | Effect of synbiotic supplementation on serum systemic inflammatory marker and serum albumin in patients admitted to ICU |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150318 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160318 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160607 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160614 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5955236 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |